Neoadjuvant Systemic and Peritoneal Chemotherapy for Advanced Gastric Cancer
Status:
Not yet recruiting
Trial end date:
2029-07-01
Target enrollment:
Participant gender:
Summary
Data demonstrating the efficacy of PIPAC in patients with regionally advanced gastric cancer
with positive peritoneal cytology and/or minimal peritoneal disease is limited due to the
relatively recent development of this technique and its historical preferential use in
palliative patients with disseminated peritoneal metastasis.
Existing data suggest PIPAC administered every six weeks in conjunction with standard
treatment may work as an adjunct to conventional systemic neoadjuvant chemotherapy. PIPAC
protocols have been established both for gastric cancer as well as other intra-abdominal
malignancies and have a good safety profile.
Given these promising findings, a study protocol is proposed herein to further investigate
PIPAC for the treatment of a highly selected group of patients with regionally advanced
gastric cancer (positive peritoneal cytology and/or minimal peritoneal disease).